Home
Home
Contact
Careers
Terms and Conditions
Privacy Policy
Cookie Policy
YouTube
X
LinkedIn
About Arcturus
RNA Medicines
Technologies
Pipeline
Clinical Trials
Business Development
Publications
Investor Relations

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults(COV002): a single-blind, randomised, controlled, phase 2/3 trial

April 13, 2021

Home
Contact
Careers
Terms and Conditions
Privacy Policy
Cookie Policy
YouTube
X
LinkedIn
© 2026 Arcturus Therapeutics, Inc.